Loading…
Treatment of the antiphospholipid syndrome
The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent rec...
Saved in:
Published in: | Autoimmunity highlights 2014-06, Vol.5 (1), p.1-7 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63 |
---|---|
cites | cdi_FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63 |
container_end_page | 7 |
container_issue | 1 |
container_start_page | 1 |
container_title | Autoimmunity highlights |
container_volume | 5 |
creator | Galli, Monica |
description | The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed. |
doi_str_mv | 10.1007/s13317-013-0056-5 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4389011</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2404294630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63</originalsourceid><addsrcrecordid>eNpdUVtLwzAYDaI4mfsBvkjBFxGqX65NXwQZ3mDgy3wOaZq6jrapSSvs35uxOdRASMI55-OcHIQuMNxigOwuYEpxlgKmKQAXKT9CZwSoTCnJ2PH-DhT4BM1CWENcNI8QnKIJEfGFOZyhm6W3emhtNySuSoaVTXQ31P3Khbibuq_LJGy60rvWnqOTSjfBzvbnFL0_PS7nL-ni7fl1_rBIDeNkSDWnuuKaZaQEo3FRYBoByYRguaiIMbSwIou2rcYGa8otK7Mo4iArwitBp-h-N7cfi9aWJnrzulG9r1vtN8rpWv1FunqlPtyXYlTmgHEccL0f4N3naMOg2joY2zS6s24MCgtJpJRMZpF69Y-6dqPvYjxFGDCSM0EhsvCOZbwLwdvqYAaD2pahdmWomEpty1A8ai5_pzgofr6efgNFTIPJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2404294630</pqid></control><display><type>article</type><title>Treatment of the antiphospholipid syndrome</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Galli, Monica</creator><creatorcontrib>Galli, Monica</creatorcontrib><description>The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed.</description><identifier>ISSN: 2038-0305</identifier><identifier>EISSN: 2038-3274</identifier><identifier>DOI: 10.1007/s13317-013-0056-5</identifier><identifier>PMID: 26000150</identifier><language>eng</language><publisher>England: Springer Nature B.V</publisher><subject>Antiphospholipid antibodies ; Antiphospholipid syndrome ; Aspirin ; Autografts ; Corticosteroids ; Heparin ; Hydroxychloroquine ; Molecular weight ; Monoclonal antibodies ; Review ; Rituximab ; Stem cell transplantation ; Thrombosis</subject><ispartof>Autoimmunity highlights, 2014-06, Vol.5 (1), p.1-7</ispartof><rights>Springer-Verlag Italia 2013.</rights><rights>Springer-Verlag Italia 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63</citedby><cites>FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389011/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2404294630?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26000150$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Galli, Monica</creatorcontrib><title>Treatment of the antiphospholipid syndrome</title><title>Autoimmunity highlights</title><addtitle>Auto Immun Highlights</addtitle><description>The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed.</description><subject>Antiphospholipid antibodies</subject><subject>Antiphospholipid syndrome</subject><subject>Aspirin</subject><subject>Autografts</subject><subject>Corticosteroids</subject><subject>Heparin</subject><subject>Hydroxychloroquine</subject><subject>Molecular weight</subject><subject>Monoclonal antibodies</subject><subject>Review</subject><subject>Rituximab</subject><subject>Stem cell transplantation</subject><subject>Thrombosis</subject><issn>2038-0305</issn><issn>2038-3274</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdUVtLwzAYDaI4mfsBvkjBFxGqX65NXwQZ3mDgy3wOaZq6jrapSSvs35uxOdRASMI55-OcHIQuMNxigOwuYEpxlgKmKQAXKT9CZwSoTCnJ2PH-DhT4BM1CWENcNI8QnKIJEfGFOZyhm6W3emhtNySuSoaVTXQ31P3Khbibuq_LJGy60rvWnqOTSjfBzvbnFL0_PS7nL-ni7fl1_rBIDeNkSDWnuuKaZaQEo3FRYBoByYRguaiIMbSwIou2rcYGa8otK7Mo4iArwitBp-h-N7cfi9aWJnrzulG9r1vtN8rpWv1FunqlPtyXYlTmgHEccL0f4N3naMOg2joY2zS6s24MCgtJpJRMZpF69Y-6dqPvYjxFGDCSM0EhsvCOZbwLwdvqYAaD2pahdmWomEpty1A8ai5_pzgofr6efgNFTIPJ</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Galli, Monica</creator><general>Springer Nature B.V</general><general>Springer International Publishing</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140601</creationdate><title>Treatment of the antiphospholipid syndrome</title><author>Galli, Monica</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antiphospholipid antibodies</topic><topic>Antiphospholipid syndrome</topic><topic>Aspirin</topic><topic>Autografts</topic><topic>Corticosteroids</topic><topic>Heparin</topic><topic>Hydroxychloroquine</topic><topic>Molecular weight</topic><topic>Monoclonal antibodies</topic><topic>Review</topic><topic>Rituximab</topic><topic>Stem cell transplantation</topic><topic>Thrombosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Galli, Monica</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Autoimmunity highlights</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Galli, Monica</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of the antiphospholipid syndrome</atitle><jtitle>Autoimmunity highlights</jtitle><addtitle>Auto Immun Highlights</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>5</volume><issue>1</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>2038-0305</issn><eissn>2038-3274</eissn><abstract>The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed.</abstract><cop>England</cop><pub>Springer Nature B.V</pub><pmid>26000150</pmid><doi>10.1007/s13317-013-0056-5</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2038-0305 |
ispartof | Autoimmunity highlights, 2014-06, Vol.5 (1), p.1-7 |
issn | 2038-0305 2038-3274 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4389011 |
source | Publicly Available Content Database; PubMed Central |
subjects | Antiphospholipid antibodies Antiphospholipid syndrome Aspirin Autografts Corticosteroids Heparin Hydroxychloroquine Molecular weight Monoclonal antibodies Review Rituximab Stem cell transplantation Thrombosis |
title | Treatment of the antiphospholipid syndrome |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T05%3A16%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20the%20antiphospholipid%20syndrome&rft.jtitle=Autoimmunity%20highlights&rft.au=Galli,%20Monica&rft.date=2014-06-01&rft.volume=5&rft.issue=1&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=2038-0305&rft.eissn=2038-3274&rft_id=info:doi/10.1007/s13317-013-0056-5&rft_dat=%3Cproquest_pubme%3E2404294630%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2404294630&rft_id=info:pmid/26000150&rfr_iscdi=true |